In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
Figure 4
Influence in body and abdominal fat pad weights of chiglitazar. (a) Male KKAy mice were orally administered daily with vehicle (Ctrl), rosiglitazone (Ros) of 5 mg kg−1, or chiglitazar (Chi) of 5 and 20 mg kg−1 for 12 days, and changes in body weight were evaluated at the indicated days. (b) and (c) Male db/db mice were orally administered daily with vehicle (Ctrl), rosiglitazone (Ros) of 5 mg kg−1, or chiglitazar (Chi) of 5, 10, and 20 mg kg−1 for 14 days. Changes in body weight were evaluated at the indicated days (b), and the fat pads were weighed from the scarified animals at day 15 (c). # compared with day 0, and * compared with Ctrl. per group for KKAy, and per group for db/db. Data are expressed as mean SE.
